Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 266

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment

Open access
Wollenberg, A., Reitamo, S., Atzori, F., Lahfa, M., Ruzicka, T., Healy, E., Giannetti, A., Bieber, T., Vyas, J., Deleuran, M., for the European Tacrolimus Ointment Study Group·2008·Allergy

Abstract

Background: Long‐term treatment for atopic dermatitis (AD) using low dose, intermittent, topical anti‐inflammatory agents may control acute disease and prevent relapses. This 12‐month, European, multicentre, randomized study investigated whether the proactive use of 0.1% tacrolimus ointment applied twice weekly can keep AD in remission and reduce the incidence of disease exacerbations (DE). Methods: During the initial open‐label period, 257 adults with AD applied 0.1% tacrolimus ointment twice daily (b.i.d.) for up to 6 weeks to affected areas. When an Investigator Global Assessment (IGA) score of ≤2 was achieved, the patient entered the disease control period (DCP) and was randomized to either proactive tacrolimus (n = 116) or vehicle ointment (n = 108) twice weekly for 12 months. Exacerbations were treated with 0.1% tacrolimus ointment b.i.d. until an IGA ≤2 was regained, then randomized treatment was restarted. The primary endpoint was the number of DEs during the DCP that required a substantial therapeutic intervention. Results: Proactive tacrolimus 0.1% ointment application significantly reduced the number of DEs requiring substantial therapeutic intervention (median difference 2; P < 0.001; Wilcoxon rank sum test), the percentage of DE treatment days (median difference: 15.2%; P < 0.001; Wilcoxon rank sum test) and increased the time to first DE (median 142 vs 15 days; P < 0.001; stratified log‐rank test). The adverse event profile was similar for the two treatment approaches. Conclusion: A 12‐month, twice weekly proactive tacrolimus ointment application was an effective treatment in most study patients which prevented, delayed and reduced the occurrence of AD exacerbations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1398-9995.2007.01406.x-i1

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 266

Metadata

Authors
Wollenberg, A., Reitamo, S., Atzori, F., Lahfa, M., Ruzicka, T., Healy, E., Giannetti, A., Bieber, T., Vyas, J., Deleuran, M., & for the European Tacrolimus Ointment Study Group
Venue
Allergy
Publisher
Wiley
Published
2008-04-25
Volume
63
Issue
6
Pages
742-750
ISSN
  • 0105-4538 (ISSN-L)
  • 1398-9995
OpenAlex
W1889663809
Cited by
266
References
18
FWCI
21.94
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. https://app.cochat.ai/papers/10.1111/j.1398-9995.2007.01406.x-i1
The paper
Wollenberg, A., Reitamo, S., Atzori, F., Lahfa, M., Ruzicka, T., Healy, E., Giannetti, A., Bieber, T., Vyas, J., Deleuran, M., & for the European Tacrolimus Ointment Study Group. (2008). Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. https://doi.org/10.1111/j.1398-9995.2007.01406.x-i1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.